Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR) - Archive ouverte HAL Access content directly
Journal Articles Gynecologic Oncology Year : 2022

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)

Olivier Trédan
  • Function : Author
Magali Provansal
  • Function : Author
Cyril Abdeddaim
  • Function : Author
Audrey Lardy-Cleaud
  • Function : Author
Anne-Claire Hardy-Bessard
  • Function : Author
Elsa Kalbacher
  • Function : Author
Anne Floquet
  • Function : Author
Laurence Venat-Bouvet
  • Function : Author
Alain Lortholary
  • Function : Author
Oana Pop
  • Function : Author
Jean-Sébastien Frenel
  • Function : Author
Mathilde Cancel
  • Function : Author
Rémy Largillier
  • Function : Author
Christophe Louvet
  • Function : Author
Benoît You
  • Function : Author
Alain Zannetti
  • Function : Author
Amelie Anota
  • Function : Author
Isabelle Treilleux
  • Function : Author
Daniel Pissaloux
  • Function : Author
Aurélie Houlier
  • Function : Author
Aude-Marie Savoye
  • Function : Author
Jérôme Meunier
  • Function : Author
Charles-Briac Levaché
  • Function : Author
Fabien Brocard
  • Function : Author
Isabelle Ray-Coquard
  • Function : Author

Dates and versions

hal-03868128 , version 1 (23-11-2022)

Identifiers

Cite

Olivier Trédan, Magali Provansal, Cyril Abdeddaim, Audrey Lardy-Cleaud, Anne-Claire Hardy-Bessard, et al.. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). Gynecologic Oncology, 2022, 164 (1), pp.18-26. ⟨10.1016/j.ygyno.2021.09.024⟩. ⟨hal-03868128⟩
7 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More